Aarti Pharmalabs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹432Cr
- −19.7% YoY
- +3.3% QoQ
- Net profit
- ₹48Cr
- −35.1% YoY
- +71.4% QoQ
- Margin
- 24%
- 0 pp YoY
- +6 pp QoQ
Guidance rank: #5 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.
From Aarti Pharmalabs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026.
- Potential for substantial growth due to small base and possible 1-2 good commercial opportunities.
- CDMO sales target: INR 1,000 crores; aiming for similar growth in FY '27 as FY '26.
- Increasing wallet share with innovator partners; around 7-8 projects anchor 80% of CDMO sales.
- New commercial molecules (from ~28 to 40) progressing to scale up revenues.
- Xanthine segment planning 25-30%+ volume growth next year; with 5-10% realization improvement due to China-related dynamics.
- API segment currently slow with some degrowth; expected to recover with new product launches and capacity expansion (including Atali plant).
2 more points from Aarti Pharmalabs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions:
- Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex.
- Xanthine site: Approved capex is around INR150 crores for both sites combined, with an ongoing capacity increase targeting 9,000 tonnes per annum by end of Q4.
- Capex at Atali includes INR450 crores total:
- INR300 crores commercialized.
- INR150 crores balance remaining.
2 more points from Aarti Pharmalabs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has single purchase orders (POs) in the range of single-digit millions of dollars, indicating sizeable orders.
- At the end of FY '25, the company had 21 CDMO customers; the number is expected to increase in calendar year 2026.
- A good number of new CDMO inquiries have been generated starting this year, with hopes to win multiple RFPs.
- The CDMO business pipeline includes 5-7 significant projects anchoring 80% of sales, with a dynamic list of about 60 projects being tracked.
- There is a mix of customers including innovators, CDMO partners, smaller biotechs, and traders.
- Some projects have wallet shares of 60-70%, indicating deep involvement in product manufacturing.
2 more points from Aarti Pharmalabs Ltd's call on order book
Create a free account to keep reading this call
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Aarti Pharmalabs Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 432 | 538 | -19.7% | 418 | +3.3% |
| Operating profit (EBITDA) | 102 | 129 | -20.9% | 74 | +37.8% |
| Operating margin | 24% | 24% | 0 pp | 18% | +6 pp |
| Profit before tax | 63 | 101 | -37.6% | 39 | +61.5% |
| Net profit (PAT) | 48 | 74 | -35.1% | 28 | +71.4% |
| EPS (₹) | 5.29 | 8.16 | -35.2% | 3.08 | +71.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q3 FY26 results?
CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions: - Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
